MPM BioImpact’s HilleVax HLVX Stock Holding History

MPM BioImpact’s Portfolio HLVX Stock Details HLVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-645,085	Closed	-$9.33M	–	49
2024 Q2	$9.33M	Buy	+645,085	New	+$8.86M	1.45%	25

Other funds holding HLVX

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

MPM BioImpact's HLVX Position: Q3 2024 in Review

MPM BioImpact sold out of HilleVax (HLVX) in Q3 2024, closing a stake of 645,085 shares — an estimated $9.33M sold.

MPM BioImpact first reported a position in HLVX in Q2 2024 and held it in 1 quarter. The position peaked at $9.33M in Q2 2024. 79 funds tracked by Wall St. Rank hold HLVX as of Q3 2024.

MPM BioImpact reported no remaining HilleVax position as of Q3 2024 after selling out during the quarter.
MPM BioImpact sold 645,085 HilleVax shares in Q3 2024, an estimated $9.33M.
MPM BioImpact first reported a position in HilleVax in Q2 2024 and held it in 1 quarter.
MPM BioImpact's HilleVax position peaked at $9.33M in Q2 2024.
79 funds tracked by Wall St. Rank held HilleVax as of Q3 2024.

Based on MPM BioImpact's 13F filing for Q3 2024, filed 13 Nov 2024.